Hemophilia More Prevalent Than Previously Estimated
|
By HospiMedica International staff writers Posted on 01 Oct 2019 |
|
A new study reveals that over 1,125,000 men around the world have inherited hemophilia, three times more than previously estimated.
Researchers at McMaster University (Hamilton, ON, Canada), the World Federation of Hemophilia (WFH; Montréal, Canada), and other institutions conducted a random-effects meta-analysis of registry data from Australia, Canada, France, Italy, New Zealand, and the United Kingdom in order to estimate the prevalence and prevalence at birth of male patients with hemophilia A or B in proportion to total male population, life expectancy disadvantage as related to prevalence at birth, and the expected number of patients worldwide.
The results revealed a prevalence of hemophilia A of 17.1 cases per 100,000 males for all severities of hemophilia, six cases for severe hemophilia A, 3.8 cases for all severities of hemophilia B, and 1.1 cases for severe hemophilia B. Prevalence at birth is 24.6 cases for all severities of hemophilia A, 9.5 cases for severe hemophilia A, five cases for all severities of hemophilia B, and 1.5 cases for severe hemophilia B. The life expectancy disadvantage (in high-income countries) is thus 30% for hemophilia A, 37% for severe hemophilia A, 24% for hemophilia B, and 27% for severe hemophilia B. The study was published on September 10, 2019, in Annals of Internal Medicine.
“The expected number of patients with hemophilia worldwide is 1,125,000, of whom 418,000 should have severe hemophilia,” said lead author Professor Alfonso Iorio, MD, PhD, director of the Hamilton-Niagara hemophilia program at McMaster University. “Knowing how many patients are out there will enable health care systems to estimate the resources needed to treat the disease, and enable drug manufacturers to increase the investment in research to match the demand of a patient population three times larger than we previously thought.”
Hemophilia, which is found almost only in men, is caused by a genetic defect. The most common type is hemophilia A, due to a lack of clotting factor VIII. Hemophilia B, which is less common, is caused by a lack in factor IX. Hemophilia is currently treated with infusions of the missing factors to prevent or stop debilitating bleeds, but treatment is expensive and scarce in many countries. Lack of treatment leads to chronic, disabling joint disease, while bleeding into organs and brain hemorrhages can lead to disability and death.
Related Links:
McMaster University
World Federation of Hemophilia
Researchers at McMaster University (Hamilton, ON, Canada), the World Federation of Hemophilia (WFH; Montréal, Canada), and other institutions conducted a random-effects meta-analysis of registry data from Australia, Canada, France, Italy, New Zealand, and the United Kingdom in order to estimate the prevalence and prevalence at birth of male patients with hemophilia A or B in proportion to total male population, life expectancy disadvantage as related to prevalence at birth, and the expected number of patients worldwide.
The results revealed a prevalence of hemophilia A of 17.1 cases per 100,000 males for all severities of hemophilia, six cases for severe hemophilia A, 3.8 cases for all severities of hemophilia B, and 1.1 cases for severe hemophilia B. Prevalence at birth is 24.6 cases for all severities of hemophilia A, 9.5 cases for severe hemophilia A, five cases for all severities of hemophilia B, and 1.5 cases for severe hemophilia B. The life expectancy disadvantage (in high-income countries) is thus 30% for hemophilia A, 37% for severe hemophilia A, 24% for hemophilia B, and 27% for severe hemophilia B. The study was published on September 10, 2019, in Annals of Internal Medicine.
“The expected number of patients with hemophilia worldwide is 1,125,000, of whom 418,000 should have severe hemophilia,” said lead author Professor Alfonso Iorio, MD, PhD, director of the Hamilton-Niagara hemophilia program at McMaster University. “Knowing how many patients are out there will enable health care systems to estimate the resources needed to treat the disease, and enable drug manufacturers to increase the investment in research to match the demand of a patient population three times larger than we previously thought.”
Hemophilia, which is found almost only in men, is caused by a genetic defect. The most common type is hemophilia A, due to a lack of clotting factor VIII. Hemophilia B, which is less common, is caused by a lack in factor IX. Hemophilia is currently treated with infusions of the missing factors to prevent or stop debilitating bleeds, but treatment is expensive and scarce in many countries. Lack of treatment leads to chronic, disabling joint disease, while bleeding into organs and brain hemorrhages can lead to disability and death.
Related Links:
McMaster University
World Federation of Hemophilia
Gold Member
12-Channel ECG
CM1200B
New
Gold Member
Handheld Blood Glucose Analyzer
STAT-Site
New
Patient Monitoring System
AlarmSense
New
Digital Radiography System (Ceiling Free)
Digix CF Series
Latest Critical Care News
- Magnetic Control System Enables Precise Navigation of Miniature Medical Devices
- Noninvasive Skull Sensor Detects Early Deterioration in Acute Brain Injury
- Bacteria-Resistant Urinary Catheter Coating Reduces Infections and Antibiotic Use
- Sensor-Integrated Airway Stent Enables Continuous Remote Monitoring
- Graphene-Based Material Selectively Eliminates Bacteria While Sparing Human Cells
- Flexible Plastic Film Uses Nanostructures to Destroy Viruses
- Finger Cuff Algorithm Enables Noninvasive Screening for Aortic Stenosis
- Vibration-Based Tools Aim to Improve Newborn Screening for Heart Defects
- Dried Platelet Biologic Reduces Hemorrhage After Traumatic Brain Injury
- Minimally Invasive Probe Measures Key Metabolic Markers Simultaneously
- AI Expands Across Heart Failure Care Continuum to Improve Management
- Wearable Cardiac Monitor with Cellular Transmission Enhances Remote Arrhythmia Detection
- Microneedle Sensor Enables Continuous Monitoring of Drug Clearance
- 3D Brain Imaging Marker Predicts Surgical Outcomes in Dementia-Causing Hydrocephalus
- Printed Artificial Neurons Stimulate Natural Brain Circuits
- Review Advances Precision Care Pathway for Meningioma Management
Channels
Artificial Intelligence
view channel
AI Model Uses Eye Imaging to Identify Risk of Major Systemic Diseases
Early detection of systemic disease risk remains a persistent challenge in population health screening. Cardiometabolic conditions such as diabetes, heart disease, and stroke often progress without symptoms... Read more
AI Platform Interprets Real-Time Wearable Data for Parkinson’s Management
Parkinson’s disease presents fluctuating motor and non-motor symptoms that complicate day-to-day self-management and clinical decision-making. Care teams require timely, longitudinal insight into medication... Read more
Surgical Techniques
view channel
New AI Tool Predicts Complications Before Lung Cancer Surgery
Lung cancer remains a leading cause of cancer mortality, and many surgical candidates present with complex comorbidities. Postoperative complications are common, making accurate and individualized risk... Read more
First Automated Insulin Delivery System Cleared for Type 1 Diabetes in Pregnancy
Managing glycemia during pregnancy complicated by type 1 diabetes requires tight targets and sustained time in a pregnancy-specific glucose range. Clinicians and patients often rely on automated insulin... Read more
Patient Care
view channel
Wearable Sleep Data Predict Adherence to Pulmonary Rehabilitation
Chronic obstructive pulmonary disease (COPD) is a long-term lung disorder that makes breathing difficult and often disturbs sleep, reducing energy for daily activities. Limited engagement in pulmonary... Read more
Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care
More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more
Health IT
view channel
AI System Detects and Quantifies Chronic Subdural Hematoma
Viz.ai (San Francisco, CA, USA) announced a strategic commercialization collaboration with Johnson & Johnson (New Brunswick, NJ, USA) to expand access in the United States to the Viz Subdural solution... Read more
Continuous Monitoring Platform Detects Infection Risk Across Care Transitions
Patients leaving skilled nursing facilities often lose continuous physiologic monitoring, increasing the risk of undetected infection and delayed intervention. Nursing home residents are seven times more... Read more
Automated System Classifies and Tracks Cardiogenic Shock Across Hospital Settings
Cardiogenic shock remains a difficult, time-sensitive emergency, with delayed identification driving poor outcomes and persistently high mortality. Many cases go undocumented even at advanced stages, hindering... Read more
Point of Care
view channel
Business
view channel
Johnson & Johnson Launches AI-Driven Cardiac Mapping System
Johnson & Johnson has introduced the CARTOSOUND SONATA Module for the CARTO System at the Heart Rhythm Society (HRS) 2026 meeting in Chicago. The module uses artificial intelligence with the CARTO... Read more
